IL205974A - 2- (5-Bromo-4- (4-Cyclopropylphenaphthalene-1-ram) -4 h-4,2,1- Triazole-3-Ilthio) Acetic acid or salt is acceptable in its pharmacy for use as a drug and a pharmaceutical preparation containing this compound - Google Patents

2- (5-Bromo-4- (4-Cyclopropylphenaphthalene-1-ram) -4 h-4,2,1- Triazole-3-Ilthio) Acetic acid or salt is acceptable in its pharmacy for use as a drug and a pharmaceutical preparation containing this compound

Info

Publication number
IL205974A
IL205974A IL205974A IL20597410A IL205974A IL 205974 A IL205974 A IL 205974A IL 205974 A IL205974 A IL 205974A IL 20597410 A IL20597410 A IL 20597410A IL 205974 A IL205974 A IL 205974A
Authority
IL
Israel
Prior art keywords
cyclopropylnaphthalen
ylthio
triazol
bromo
medicament
Prior art date
Application number
IL205974A
Other languages
English (en)
Hebrew (he)
Other versions
IL205974A0 (en
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL205974(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of IL205974A0 publication Critical patent/IL205974A0/en
Publication of IL205974A publication Critical patent/IL205974A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL205974A 2007-11-27 2010-05-26 2- (5-Bromo-4- (4-Cyclopropylphenaphthalene-1-ram) -4 h-4,2,1- Triazole-3-Ilthio) Acetic acid or salt is acceptable in its pharmacy for use as a drug and a pharmaceutical preparation containing this compound IL205974A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99057407P 2007-11-27 2007-11-27
US9438808P 2008-09-04 2008-09-04
PCT/US2008/084988 WO2009070740A2 (en) 2007-11-27 2008-11-26 Novel compounds and compositions and methods of use

Publications (2)

Publication Number Publication Date
IL205974A0 IL205974A0 (en) 2010-11-30
IL205974A true IL205974A (en) 2015-03-31

Family

ID=40679222

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205974A IL205974A (en) 2007-11-27 2010-05-26 2- (5-Bromo-4- (4-Cyclopropylphenaphthalene-1-ram) -4 h-4,2,1- Triazole-3-Ilthio) Acetic acid or salt is acceptable in its pharmacy for use as a drug and a pharmaceutical preparation containing this compound

Country Status (35)

Country Link
US (8) US8084483B2 (cg-RX-API-DMAC7.html)
EP (2) EP2842948A1 (cg-RX-API-DMAC7.html)
JP (3) JP5099794B2 (cg-RX-API-DMAC7.html)
KR (2) KR101291643B1 (cg-RX-API-DMAC7.html)
CN (3) CN103058944B (cg-RX-API-DMAC7.html)
AR (1) AR069753A1 (cg-RX-API-DMAC7.html)
AU (2) AU2008329673C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0819847B1 (cg-RX-API-DMAC7.html)
CA (1) CA2706858C (cg-RX-API-DMAC7.html)
CL (1) CL2008003529A1 (cg-RX-API-DMAC7.html)
CY (1) CY2019010I1 (cg-RX-API-DMAC7.html)
DK (1) DK2217577T3 (cg-RX-API-DMAC7.html)
EA (2) EA018193B3 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010310A (cg-RX-API-DMAC7.html)
ES (1) ES2513390T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140950T1 (cg-RX-API-DMAC7.html)
HU (1) HUS1900009I1 (cg-RX-API-DMAC7.html)
IL (1) IL205974A (cg-RX-API-DMAC7.html)
LT (1) LTPA2019003I1 (cg-RX-API-DMAC7.html)
LU (1) LUC00103I2 (cg-RX-API-DMAC7.html)
MA (1) MA31936B1 (cg-RX-API-DMAC7.html)
ME (2) ME01294B (cg-RX-API-DMAC7.html)
MX (1) MX2010005776A (cg-RX-API-DMAC7.html)
MY (1) MY147370A (cg-RX-API-DMAC7.html)
NO (1) NO2016016I1 (cg-RX-API-DMAC7.html)
NZ (4) NZ601774A (cg-RX-API-DMAC7.html)
PL (1) PL2217577T3 (cg-RX-API-DMAC7.html)
PT (1) PT2217577E (cg-RX-API-DMAC7.html)
RS (1) RS53569B1 (cg-RX-API-DMAC7.html)
SG (1) SG183721A1 (cg-RX-API-DMAC7.html)
SI (1) SI2217577T1 (cg-RX-API-DMAC7.html)
TN (1) TN2010000237A1 (cg-RX-API-DMAC7.html)
TW (1) TWI415840B (cg-RX-API-DMAC7.html)
WO (1) WO2009070740A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003769B (cg-RX-API-DMAC7.html)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
PT2135608E (pt) * 2004-08-25 2012-01-13 Ardea Biosciences Inc S-triazolil-alfa-mercaptoacetanilidas como inibidores de transcritase inversa de vih
US8084483B2 (en) 2007-11-27 2011-12-27 Ardea Biosciences, Inc. Compounds and compositions and methods of use
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
JP2012502049A (ja) * 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
WO2010048593A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010048592A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010135530A2 (en) * 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels
US8372807B2 (en) 2009-05-20 2013-02-12 Ardea Biosciences, Inc. Methods of modulating uric acid levels
EA020183B1 (ru) * 2010-01-08 2014-09-30 Ардеа Биосайнсиз, Инк. Полиморфная, кристаллическая и мезофазная формы 2-(5-бром-4-(4-циклопропилнафталинил-1-ил)-4н-1,2,4-триазол-3-илтио)ацетата натрия и их применение
EP3659601A1 (en) * 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
PT2582683T (pt) * 2010-06-15 2018-05-25 Ardea Biosciences Inc Tratamento da gota e de hiperuricemia
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
WO2011159840A2 (en) * 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
CN106176736A (zh) * 2010-10-15 2016-12-07 阿迪亚生命科学公司 用于治疗高尿酸血症及相关疾病的方法
CN103200821A (zh) * 2010-10-28 2013-07-10 Mapi医药公司 非布索坦的多晶型物
CA2817249C (en) * 2010-12-30 2015-02-10 Ardea Biosciences, Inc. Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof
WO2012122532A2 (en) * 2011-03-09 2012-09-13 Biocryst Pharmaceuticals, Inc. Compositions and methods for treatment of hyperuricemia
RS56225B1 (sr) * 2011-05-24 2017-11-30 Ardea Biosciences Inc Hipertenzija i hiperurikemija
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104023723B (zh) 2011-11-03 2017-05-31 阿迪亚生命科学公司 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物
SG11201401981TA (en) * 2011-11-04 2014-05-29 Metabolex Inc Methods for treating gout flares
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
AU2011380509B2 (en) * 2011-11-04 2016-05-19 Cymabay Therapeutics, Inc. Methods for treating gout in patient subpopulations
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
RU2014134845A (ru) * 2012-01-27 2016-03-20 Тейдзин Фарма Лимитед Терапевтическое средство против диабета
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
MX2015003672A (es) * 2012-11-14 2015-06-15 Teijin Pharma Ltd Derivados de piridina.
CN102973530B (zh) * 2012-12-14 2016-08-03 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法
KR102240158B1 (ko) 2013-05-13 2021-04-15 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
CN105263913B (zh) * 2013-06-14 2017-12-15 广东东阳光药业有限公司 硫代1,2,4‑三唑衍生物及其制备方法
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN104447589B (zh) * 2013-11-20 2017-01-11 广东东阳光药业有限公司 一种尿酸调节剂的制备方法及其中间体
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CA2931430A1 (en) * 2013-11-22 2015-05-28 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad and its sodium salt
CN103588716A (zh) * 2013-11-22 2014-02-19 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的新晶型及其制备方法
CN103626710A (zh) * 2013-12-20 2014-03-12 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的共晶及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
US9969701B2 (en) * 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
CN105294585B (zh) * 2014-07-02 2019-02-12 成都海创药业有限公司 一种治疗痛风的化合物
CN104068288B (zh) * 2014-07-25 2016-08-24 许伟琦 一种防尿路结石的饲料添加剂
CN104326995A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326994A (zh) * 2014-10-27 2015-02-04 张远强 一种腈基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341365A (zh) * 2014-10-27 2015-02-11 张远强 卤代三氮唑丙二酸类化合物、其制备方法及用途
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341364A (zh) * 2014-10-27 2015-02-11 张远强 三氮唑丙二酸类化合物、其制备方法及用途
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104326996A (zh) * 2014-10-27 2015-02-04 张远强 一种硝基取代三氮唑丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104529848A (zh) * 2014-11-10 2015-04-22 安徽万邦医药科技有限公司 一种1-环丙基-4-异硫氰酰基萘的合成方法
EP4349414B1 (en) 2014-12-23 2025-10-15 Dyve Biosciences, Inc. Formulations for transdermal administration
CA2971125C (en) * 2014-12-29 2024-05-21 Nippon Chemiphar Co., Ltd. Urat1 inhibitor
CN109053608A (zh) * 2015-02-17 2018-12-21 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物、其药物组合物和用途
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
CN104710374A (zh) * 2015-04-14 2015-06-17 安徽省逸欣铭医药科技有限公司 一种痛风新化合物及制备方法、用途及其药物制剂
CN106187926B (zh) 2015-04-30 2018-11-27 天津药物研究院有限公司 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017033963A1 (ja) * 2015-08-26 2017-03-02 株式会社スタージェン 細胞内ａｔｐ増強剤
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105301126B (zh) * 2015-10-10 2021-02-12 大道隆达（北京）医药科技发展有限公司 一种托匹司他有关物质的分析方法
EP3380970B1 (en) 2015-11-24 2023-01-04 Sanford Burnham Prebys Medical Discovery Institute Novel azole derivatives as apelin receptor agonist
JP6898330B2 (ja) * 2015-12-28 2021-07-07 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド インドリジン誘導体、組成物、及び使用方法
WO2017147270A1 (en) * 2016-02-24 2017-08-31 Ardea Biosciences, Inc. Atropisomers of triazole derivative
CN107176930B (zh) * 2016-03-11 2020-12-01 广东赛烽医药科技有限公司 2-[5-溴-4-(4-氟代环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基]乙酸化合物及其应用
CN107337649B (zh) * 2016-04-29 2020-10-16 四川科伦药物研究院有限公司 一种乙酸钠水合物无定型及其制备方法和用途
US10829483B2 (en) 2016-05-23 2020-11-10 Cstone Pharmaceutical (Suzhou) Co., Ltd. Thiophene, manufacturing method thereof, and pharmaceutical application of same
CN106074540B (zh) * 2016-06-10 2018-10-16 江西博屾医疗器械有限公司 一种用于高尿酸血症治疗的药物组合物及其应用
CN105943552A (zh) * 2016-06-17 2016-09-21 王枝宝 一种氢氧化钾的医药用途
ES2931470T3 (es) * 2016-06-17 2022-12-29 Medshine Discovery Inc Compuesto halogenado e isómero axialmente quiral del mismo
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
CZ2016611A3 (cs) * 2016-09-30 2018-05-09 Zentiva, K.S. Způsob výroby 2-(5-brom-4-(1-cyklopropylnaftalen-4-yl)-4H-1,2,4-triazol-3-ylthio)octové kyseliny - lesinuradu
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
WO2018085932A1 (en) 2016-11-10 2018-05-17 Apotex Inc. Novel crystalline forms of lesinurad
US11453858B2 (en) 2016-11-11 2022-09-27 Whitehead Institute For Biomedical Research Human plasma-like medium
CN108164471B (zh) * 2016-12-07 2019-09-13 浙江京新药业股份有限公司 Lesinurad衍生物及其制备方法和用途
US10351537B2 (en) 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (en) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphous form of lesinurad and processes for its preparation
CN108947919B (zh) * 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
WO2018218250A2 (en) * 2017-05-26 2018-11-29 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
CA3083295C (en) 2017-11-23 2021-05-04 Medshine Discovery Inc. Crystal form of urat1 inhibitor, and preparation method therefor
EP3498697A1 (en) 2017-12-12 2019-06-19 Química Sintética, S.A. Novel salts and polymorphs of lesinurad
US11352331B2 (en) 2017-12-15 2022-06-07 Medshine Discovery Crystal and salt of 4-(naphthalen-1-yl)-4H-1,2,4-triazole compound and preparation method therefor
AU2019266303B2 (en) 2018-05-09 2025-12-18 Vibrant Holdings, Llc Methods of synthesizing a polynucleotide array using photactivated agents
KR20210052389A (ko) 2018-08-27 2021-05-10 리제너론 파마슈티칼스 인코포레이티드 다운스트림 정제에서의 라만 분광법의 사용
CN109369783B (zh) * 2018-11-30 2021-09-10 昆明医科大学 一种多肽rdp1及其提纯方法与应用
CN111320588B (zh) * 2018-12-14 2024-02-09 上海奥博生物医药股份有限公司 一种纯化Lesinurad的方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006101A (en) 1932-07-05 1935-06-25 Meaf Mach En Apparaten Fab Nv Reversing mechanism for dry gas meters
NL7112373A (cg-RX-API-DMAC7.html) * 1970-09-25 1972-03-28
US4198513A (en) * 1970-09-25 1980-04-15 Merck & Co., Inc. 1,2,4-Triazoles
JPS5641637B2 (cg-RX-API-DMAC7.html) 1973-11-26 1981-09-29
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5260322A (en) * 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US6832996B2 (en) * 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
US6245817B1 (en) * 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
CA2251368A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
JP2002529469A (ja) 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関する方法
WO2000037471A1 (en) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
US6593077B2 (en) * 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6995283B2 (en) 2001-03-02 2006-02-07 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
PL208260B1 (pl) 2002-01-28 2011-04-29 Fuji Yakuhin Co Związki 1,2,4-triazolu, lek zawierający związek oraz zastosowanie związku
AU2003222648A1 (en) 2002-05-13 2003-12-02 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
US20060135556A1 (en) * 2002-08-23 2006-06-22 Jean-Luc Girardet Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
AP2065A (en) 2003-02-07 2009-11-26 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
MXPA06002069A (es) 2003-09-25 2006-05-19 Janssen Pharmaceutica Nv Derivados de purina que inhiben la replicacion del vih.
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US8236488B2 (en) 2003-11-14 2012-08-07 Human Cell Systems, Inc. Method of screening for therapeutic compounds for vascular disorders and hypertension based on URAT1 activity modulation
MXPA06007054A (es) 2003-12-19 2007-04-17 Elixir Pharmaceuticals Inc Metodos para tratar una enfermedad.
EP1723123A4 (en) * 2004-03-08 2009-12-02 Wyeth Corp ION CHANNEL MODULATORS
CN1934095A (zh) * 2004-03-08 2007-03-21 惠氏公司 离子通道调节剂
BRPI0511510A (pt) 2004-05-25 2007-12-26 Metabolex Inc composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo
US20060013556A1 (en) 2004-07-01 2006-01-19 Thomas Poslinski Commercial information and guide
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
PT2135608E (pt) 2004-08-25 2012-01-13 Ardea Biosciences Inc S-triazolil-alfa-mercaptoacetanilidas como inibidores de transcritase inversa de vih
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
WO2007043401A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれを含有する医薬組成物
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
AU2007267803B2 (en) 2006-05-25 2011-08-25 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
CA2653217A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
CN101646440A (zh) 2007-01-19 2010-02-10 武田制药北美公司 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法
US8084483B2 (en) 2007-11-27 2011-12-27 Ardea Biosciences, Inc. Compounds and compositions and methods of use
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
RS56225B1 (sr) 2011-05-24 2017-11-30 Ardea Biosciences Inc Hipertenzija i hiperurikemija

Also Published As

Publication number Publication date
AU2008329673A1 (en) 2009-06-04
CN102643241B (zh) 2015-01-21
US20160221970A1 (en) 2016-08-04
MA31936B1 (fr) 2010-12-01
NO2016016I2 (no) 2016-08-17
DK2217577T3 (da) 2014-10-20
PL2217577T3 (pl) 2015-01-30
EA018193B3 (ru) 2014-07-30
ZA201003769B (en) 2011-02-23
NO2016016I1 (no) 2016-08-17
US20090197825A1 (en) 2009-08-06
SG183721A1 (en) 2012-09-27
EA201270666A1 (ru) 2012-12-28
JP2011504935A (ja) 2011-02-17
MY147370A (en) 2012-11-30
US20110268801A1 (en) 2011-11-03
NZ601774A (en) 2013-07-26
US8357713B2 (en) 2013-01-22
CA2706858A1 (en) 2009-06-04
KR101291643B1 (ko) 2013-08-01
ECSP10010310A (es) 2010-07-30
TN2010000237A1 (en) 2011-11-11
TW200927733A (en) 2009-07-01
ME01294B (me) 2013-06-20
WO2009070740A2 (en) 2009-06-04
LTPA2019003I1 (lt) 2019-02-25
CN103058944B (zh) 2015-08-05
US20190142805A1 (en) 2019-05-16
LUC00103I2 (cg-RX-API-DMAC7.html) 2019-12-27
EA201000897A1 (ru) 2010-12-30
ME01996B (me) 2015-05-20
KR20100085195A (ko) 2010-07-28
US20110293719A1 (en) 2011-12-01
US10183012B2 (en) 2019-01-22
HK1180337A1 (en) 2013-10-18
NZ595035A (en) 2012-11-30
ES2513390T3 (es) 2014-10-27
AU2008329673B2 (en) 2012-04-12
JP2014196373A (ja) 2014-10-16
WO2009070740A3 (en) 2009-08-13
HK1172326A1 (en) 2013-04-19
JP5905934B2 (ja) 2016-04-20
BRPI0819847A2 (pt) 2020-10-06
BRPI0819847B1 (pt) 2022-01-11
EP2217577A4 (en) 2010-12-08
US8084483B2 (en) 2011-12-27
CN103058944A (zh) 2013-04-24
SI2217577T1 (sl) 2014-11-28
JP2012184234A (ja) 2012-09-27
HUS1900009I1 (hu) 2019-03-28
AU2012203172B2 (en) 2013-10-10
KR101411806B1 (ko) 2014-06-24
KR20120084787A (ko) 2012-07-30
CN101918377A (zh) 2010-12-15
US8546437B2 (en) 2013-10-01
US20120164222A1 (en) 2012-06-28
MX2010005776A (es) 2010-08-31
CN102643241A (zh) 2012-08-22
CY2019010I2 (el) 2019-11-27
EA018193B1 (ru) 2013-06-28
AU2012203172A1 (en) 2012-06-21
EP2217577B1 (en) 2014-08-06
EP2842948A1 (en) 2015-03-04
CY2019010I1 (el) 2019-11-27
HRP20140950T1 (hr) 2014-12-05
PT2217577E (pt) 2014-10-20
RS53569B1 (sr) 2015-02-27
TWI415840B (zh) 2013-11-21
AU2008329673C1 (en) 2012-10-25
NZ601786A (en) 2014-02-28
NZ585583A (en) 2011-09-30
AR069753A1 (es) 2010-02-17
US8283369B2 (en) 2012-10-09
IL205974A0 (en) 2010-11-30
CA2706858C (en) 2013-12-24
JP5099794B2 (ja) 2012-12-19
LUC00103I1 (cg-RX-API-DMAC7.html) 2019-02-19
US20140005136A1 (en) 2014-01-02
EP2217577A2 (en) 2010-08-18
CL2008003529A1 (es) 2009-11-27
US20170281601A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
IL205974A (en) 2- (5-Bromo-4- (4-Cyclopropylphenaphthalene-1-ram) -4 h-4,2,1- Triazole-3-Ilthio) Acetic acid or salt is acceptable in its pharmacy for use as a drug and a pharmaceutical preparation containing this compound
WO2011085009A3 (en) Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
IL212033A0 (en) A controlled release pharmaceutical composition comprising (r)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl] acetic acid aniolide and a process for producing the same
WO2012092395A3 (en) Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof
IL192150A (en) Use of 2-amino-2- [4- (3-benzyloxyphenylthio) -2-chlorophyll} ethyl-1,3-propanadiol, or its acceptable medical salt or hydrate, for the preparation or treatment of inflammatory bowel disease
ZA200809002B (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
IL192298A (en) Heterocyclic Compounds, Their Acceptable Salts, Pharmaceuticals Containing and Using Them
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
SI1789021T1 (sl) Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol
IL199397A (en) Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products
IL199835A (en) Acid-activated antimicrobial peptides, their pharmaceutical preparations, and their use in drug preparation
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
BRPI0720637A2 (pt) Composto ou um sal farmaceuticamente aceitável, uma forma estereoisomérica, tautomérica ou polimórfica do mesmo, métodos para o tratamento de um hospedeiro e de tratamento de infecção, composição farmacêutica, e, uso do composto
PL2099297T3 (pl) Środki poprawiające zgodność dla preparatów herbicydów zawierających sole kwasu 2,4-(dichlorofenoksy)octowego
IL233334A (en) Compounds 3– (optionally converted aromatic hydrochloride and elliptic hydrocarbyl) –1 - [(5-oxo-5,4-dihydro-1h – 4,2,1-triazole-3-ram) methyl] -pyridine-2– (1h) - On, the pharmacy composition containing and using them
IL205102A (en) Triazole Derivatives - 5, 3, 1 - Tri-Conjugated, Pharmaceutical Preparation and Container Kit
WO2009150118A3 (en) Novel salts of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid
EP2196206B8 (en) Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
HUE026549T2 (hu) 1-N-azacikloalkil-3-fenoxipropán pszichotróp gyógyszerek elõállítására alkalmas származékai
IL201832A (en) Medicines containing a combination of acid 4- [3, 5-bis (2-hydroxyphenyl) - [1, 2, 4] triazole-1-ram] benzoic or its common pharmacy salt and aminoglucoside antibiotics
IL185926A (en) Annals of 2 - (3,1-Dihydro-H2-Benzimidazole-2-Illiden) -1-Alkylamidinosulfonylphenyl-3 - (Phenyl or Thienyl) -Propane-3,1
IL206514A0 (en) Triazole oxadiazoles derivatives, their preparation and pharmaceutical compositions containing them
WO2008151811A3 (de) Verfahren zur herstellung eines arzneimittels enthaltend vardenafil hydrochlorid trihydrat
WO2009038412A3 (en) Beta-secretase inhibiting compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed